US-China Biomedical Technology, Inc.: 10-K filed 2014-06-13
What US-China Biomedical Technology, Inc. reported in its annual report filed 2014-06-13 (fiscal FY 2014): 19 published measures, 48 facts as tagged in accession 0001213900-14-004195.
This filing
- Form
- 10-K (annual report)
- Filed
- 2014-06-13
- Fiscal period
- fiscal FY 2014
- Accession
- 0001213900-14-004195 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All US-China Biomedical Technology, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | 197 | USD | |
| At 2013-02-28 | 87,581 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | -150,369 | USD | |
| At 2013-02-28 | 56,110 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | 22 | USD | |
| At 2013-02-28 | 87,281 | USD | |
| At 2012-02-29 | 13,658 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | -1,019,869 | USD | 365 |
| 2011-10-18 to 2014-02-28 | -1,352,926 | USD | 865 |
| 2012-03-01 to 2013-02-28 | -262,794 | USD | 365 |
| 2011-10-18 to 2012-02-29 | -70,263 | USD | 135 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | -285,884 | USD | 365 |
| 2011-10-18 to 2014-02-28 | -399,495 | USD | 865 |
| 2012-03-01 to 2013-02-28 | -58,448 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | 125 | USD | 365 |
| 2011-10-18 to 2014-02-28 | -61,454 | USD | 865 |
| 2012-03-01 to 2013-02-28 | -30,300 | USD | 365 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | 97,695,779 | shares | 365 |
| 2012-03-01 to 2013-02-28 | 88,842,740 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | -0.01 | USD/shares | 365 |
| 2012-03-01 to 2013-02-28 | 0 | USD/shares | 365 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | 818 | USD | 365 |
| 2011-10-18 to 2014-02-28 | 1,618 | USD | 865 |
| 2012-03-01 to 2013-02-28 | 800 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | -844,861 | USD | 365 |
| 2011-10-18 to 2014-02-28 | -1,176,500 | USD | 865 |
| 2012-03-01 to 2013-02-28 | -261,476 | USD | 365 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | 150,566 | USD | |
| At 2013-02-28 | 31,471 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | 78,916 | USD | |
| At 2013-02-28 | 26,321 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | 99,858,086 | shares | |
| At 2013-02-28 | 97,200,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | 1,171,453 | USD | |
| At 2013-02-28 | 360,721 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-02-28 | -150,369 | USD | |
| At 2013-02-28 | 56,110 | USD | |
| At 2012-02-29 | -55,163 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | -1,019,051 | USD | 365 |
| 2011-10-18 to 2014-02-28 | -1,351,308 | USD | 865 |
| 2012-03-01 to 2013-02-28 | -261,994 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | 302,257 | USD | 365 |
| 2011-10-18 to 2014-02-28 | 572,617 | USD | 865 |
| 2012-03-01 to 2013-02-28 | 200,197 | USD | 365 |
Current income tax expense or benefit
Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-03-01 to 2014-02-28 | 818 | USD | 365 |
| 2011-10-18 to 2014-02-28 | 1,618 | USD | 865 |
| 2012-03-01 to 2013-02-28 | 800 | USD | 365 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-10-18 to 2014-02-28 | 100 | USD | 865 |
Inspect the source
- Entity
- US-China Biomedical Technology, Inc. / CIK 0001516079
- Captured
- SEC response SHA-256
c9cfb34f55b1d35452520c1453439439cbecbb44d0f2e8be8d980937632dd9ff
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001516079.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))